<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01682876</url>
  </required_header>
  <id_info>
    <org_study_id>V59_57</org_study_id>
    <nct_id>NCT01682876</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.</brief_title>
  <official_title>A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to conduct a comparative trial to further evaluate the safety,
      immunogenicity and antibody persistence of two doses of Novartis MenACWY conjugate vaccine,
      given 2 months apart, versus one dose of Novartis MenACWY conjugate vaccine in children 2
      through 10 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination</measure>
    <time_frame>One Month After Last Vaccination ( day 86)</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 97.5% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y, by serum bactericidal assay using human complement (hSBA) at 1 month after one vaccination or two vaccinations of MenACWY-CRM given two months apart.
Seroresponse is defined as:
postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer &lt;1:4;
for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination</measure>
    <time_frame>One Month After Last Vaccination (day 86)</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 95% CI, directed against N. meningitidis serogroups A, C, W and Y, by hSBA at 1 month after one vaccination or two vaccinations of MenACWY-CRM. Seroresponse -postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer &lt;1:4 and for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM</measure>
    <time_frame>One Month After Last Vaccination (day 86)</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects who achieved hSBA titer ≥1:8 and associated 95% CI, at one month after one vaccination or two vaccinations of MenACWY-CRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM</measure>
    <time_frame>One Month After Last Vaccination (day 86)</time_frame>
    <description>Immunogenicity was measured as hSBA geometric mean titers (GMTs) and 95% CI against N. meningitidis serogroups A, C, W and Y, one month after one vaccination or two vaccinations of MenACWY-CRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM</measure>
    <time_frame>One year after one vaccination or two vaccinations (day 422).</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI at one year after one vaccination or two vaccinations of MenACWY-CRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM</measure>
    <time_frame>One year after one vaccination or two vaccinations (day 422).</time_frame>
    <description>Immunogenicity was measured as hSBA GMTs and 95% CI against N. meningitidis serogroups A, C, W and Y at one year after one vaccination or two vaccinations of MenACWY-CRM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of 2 to 5 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</measure>
    <time_frame>From Days 1-7 after each vaccination</time_frame>
    <description>Safety was assessed as the number of 2 to 5 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of 6 to 10 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</measure>
    <time_frame>From Days 1-7 after each vaccination</time_frame>
    <description>Safety was assessed as the number of 6 to 10 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Selected AEs After Any Vaccination</measure>
    <time_frame>Day 1 to Day 86</time_frame>
    <description>Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 86 after one or two vaccination(s) of MenACWY-CRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Selected AEs After Any Vaccination</measure>
    <time_frame>Day 1 to Day 422</time_frame>
    <description>Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 422 after one or two vaccination(s) of MenACWY-CRM</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>2 through 5 years (1 Vac) MenACWY-CRM 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects 2 through 5 years received one vaccination of MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 through 5 years (2 Vac) MenACWY-CRM 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects 2 through 5 years received two vaccinations of MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 through 10 years (1 Vac) MenACWY-CRM 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects 6 through 10 years received one vaccination of MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 through 10 years (2 Vac) MenACWY-CRM 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects 6 through 10 years received two vaccinations of MenACWY-CRM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm</description>
    <arm_group_label>2 through 5 years (1 Vac) MenACWY-CRM 1</arm_group_label>
    <arm_group_label>2 through 5 years (2 Vac) MenACWY-CRM 2</arm_group_label>
    <arm_group_label>6 through 10 years (1 Vac) MenACWY-CRM 3</arm_group_label>
    <arm_group_label>6 through 10 years (2 Vac) MenACWY-CRM 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children, 2 to 10 years of age who have up to date routine childhood
             vaccination, according to U.S. ACIP recommendations

        Exclusion Criteria:

          1. Unwilling or unable to give written informed assent or consent to participate in the
             study.

          2. Perceived to be unreliable or unavailable for the duration of the study period.

          3. Previous confirmed or suspected disease caused by N. meningitidis.

          4. Previously immunized with a meningococcal vaccine (licensed or investigational).

          5. Receipt of any investigational or non-registered product within 30 days prior to
             enrolment or who expect to receive an investigational drug or vaccine prior to the
             completion of the study.

          6. Receipt or plan to receive any vaccines within 30 days before and after administration
             of each dose of the study vaccine.

             (certain exceptions influenza vaccines apply)

          7. Significant acute infection within the 7 days prior to enrolment or body temperature
             of 38°C or greater within 3 days prior to enrolment.

          8. Previous serious acute, chronic or progressive disease, epilepsy or any progressive
             neurological disease or history of Guillain-Barre syndrome.

          9. History of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine
             components

         10. Impairment/alteration of immune function, either congenital or acquired or resulting
             from (for example):

               -  receipt of immunosuppressive therapy,

               -  receipt of immunostimulants,

               -  receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives.

         11. Known bleeding diathesis, or any condition that may be associated with a prolonged
             bleeding time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 12 - Alabama Clinical Therapeutics, LLC 52 Medical Park East Drive, Suite 203</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13 - Benchmark Research,1355 Florin Road, Suite 10</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5 - Altamonte Pediatric Associates 101 N Country Club Rd, Suite 115</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10 - Pediatrics and Adolescent Medicine 2155 Post Oak Tritt Rd, Suite 100</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11 - Pediatrics and Adolescent Medicine 120 Stonebridge Parkway, Suite 410</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4 - Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>46298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16 - Ridge Family Practice, 201 Ridge Street, Suite 201</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3 - Brownboro Park Pediatrics. 5512 Bardstown Rd, Suite 2</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15 - Benchmark Research, 3800 Houma Blvd., Suite 345</name>
      <address>
        <city>Metaire</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2 - Southwestern Medical Clinic</name>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7 - Southwestern Medical Clinic, Lakeland HealthCare Affiliate</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18 - Bellevue Family Practice/Clinical Research Advantage 2206 Longo, Suite 201</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6 - Meridian Clinical Research, Meridian Clinical Research 1103 Galvin Road South #G</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17 - Prairie Fields Family Medicine/Clinical Research Advantage, Inc., 350 W. 23rd Street, Suite A</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24 - Pediatric Partners 750 East 29th St.</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1 - Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14 - United Medical Associates, PC., 4417 Vestal Parkway East</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23 - Rapid Medical Research, Inc., 3619 Park East Dr., Suite 300</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19 - Senders Pediatrics 2054 South Green Road</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8 - Benchmark Research, 1015 E 32nd Street, Suite 303</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9 - Benchmark Research, 4504 Boat Club Rd., Suite 400A</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20 - Advanced Clinical Research, 3590 West 9000 South, Suite 300</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2012</study_first_posted>
  <results_first_submitted>June 6, 2014</results_first_submitted>
  <results_first_submitted_qc>September 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2014</results_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of meningococcal disease, children, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 22 locations</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2 Through 5 Years (2 Vac)</title>
          <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
        </group>
        <group group_id="P2">
          <title>2 Through 5 Years (1 Vac)</title>
          <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
        </group>
        <group group_id="P3">
          <title>6 Through 10 Years (2 Vac)</title>
          <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
        </group>
        <group group_id="P4">
          <title>6 Through 10 Years (1 Vac)</title>
          <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="180"/>
                <participants group_id="P4" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="169"/>
                <participants group_id="P4" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 Through 5 Years (2 Vac)</title>
          <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
        </group>
        <group group_id="B2">
          <title>2 Through 5 Years (1 Vac)</title>
          <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
        </group>
        <group group_id="B3">
          <title>6 Through 10 Years (2 Vac)</title>
          <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
        </group>
        <group group_id="B4">
          <title>6 Through 10 Years (1 Vac)</title>
          <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="180"/>
            <count group_id="B4" value="176"/>
            <count group_id="B5" value="715"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="1.1"/>
                    <measurement group_id="B2" value="3.6" spread="1.2"/>
                    <measurement group_id="B3" value="7.8" spread="1.4"/>
                    <measurement group_id="B4" value="7.8" spread="1.4"/>
                    <measurement group_id="B5" value="5.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination</title>
        <description>Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 97.5% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y, by serum bactericidal assay using human complement (hSBA) at 1 month after one vaccination or two vaccinations of MenACWY-CRM given two months apart.
Seroresponse is defined as:
postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer &lt;1:4;
for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.</description>
        <time_frame>One Month After Last Vaccination ( day 86)</time_frame>
        <population>Analysis was done on the primary per-protocol (PP) dataset, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination</title>
          <description>Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 97.5% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y, by serum bactericidal assay using human complement (hSBA) at 1 month after one vaccination or two vaccinations of MenACWY-CRM given two months apart.
Seroresponse is defined as:
postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer &lt;1:4;
for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.</description>
          <population>Analysis was done on the primary per-protocol (PP) dataset, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA(N=135,143,152,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O2" value="75" lower_limit="67" upper_limit="82"/>
                    <measurement group_id="O3" value="89" lower_limit="83" upper_limit="93"/>
                    <measurement group_id="O4" value="77" lower_limit="70" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC(N=131,140,149,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O2" value="65" lower_limit="56" upper_limit="73"/>
                    <measurement group_id="O3" value="93" lower_limit="87" upper_limit="96"/>
                    <measurement group_id="O4" value="73" lower_limit="65" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW(N=128,135,148,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="67" upper_limit="82"/>
                    <measurement group_id="O2" value="61" lower_limit="52" upper_limit="69"/>
                    <measurement group_id="O3" value="58" lower_limit="50" upper_limit="66"/>
                    <measurement group_id="O4" value="54" lower_limit="45" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY(N=128,133,148,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="84" upper_limit="95"/>
                    <measurement group_id="O2" value="64" lower_limit="55" upper_limit="72"/>
                    <measurement group_id="O3" value="89" lower_limit="83" upper_limit="94"/>
                    <measurement group_id="O4" value="60" lower_limit="51" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs.one vaccination for age cohort (2 to 5 years of age) for MenA</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 2 to 5 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenA</non_inferiority_desc>
            <param_type>Vaccine Group Differences at Day 86</param_type>
            <param_value>19</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10</ci_lower_limit>
            <ci_upper_limit>28.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs. one vaccination for age cohort (2 to 5 years of age) for MenC</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 2 to 5 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenC</non_inferiority_desc>
            <param_type>Vaccine Group Differences at Day 86</param_type>
            <param_value>27</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.9</ci_lower_limit>
            <ci_upper_limit>37.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs. one vaccination for age cohort (2 to 5 years of age) for MenW</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 2 to 5 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenW</non_inferiority_desc>
            <param_type>Vaccine Group Differences at Day 86</param_type>
            <param_value>14</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>26.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs. one vaccination for age cohort (2 to 5 years of age) for MenY</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 2 to 5 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for Men Y</non_inferiority_desc>
            <param_type>Vaccine Group differences at Day 86</param_type>
            <param_value>27</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.6</ci_lower_limit>
            <ci_upper_limit>37.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs. one vaccination for age cohort (6 to 10 years of age) for MenA</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 6 to 10 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenA</non_inferiority_desc>
            <param_type>Vaccines Group Differences at Day 86</param_type>
            <param_value>11</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs. one vaccination for age cohort (6 to 10 years of age) for MenC</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 6 to 10 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenC</non_inferiority_desc>
            <param_type>Vaccines Group differences at Day 86</param_type>
            <param_value>19</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.9</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse of two vaccinations vs. one vaccination for age cohort (6 to 10 years of age) for MenW</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 6 to 10 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenW</non_inferiority_desc>
            <param_type>Vaccines Group Differences at Day 86</param_type>
            <param_value>4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>17.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse for two vaccinations vs. one vaccination for age cohort (6 to 10 years of age) for MenY</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority was demonstrated for 6 to 10 years of age group if the lower limit of the 2-sided 97.5% confidence interval (CI) for the difference in seroresponse rate between the 2-dose vaccination schedule and the 1-dose vaccination schedule (2-dose schedule minus the 1-dose schedule) was greater than -10% for MenY</non_inferiority_desc>
            <param_type>Vaccines Group Differences at Day 86</param_type>
            <param_value>29</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.4</ci_lower_limit>
            <ci_upper_limit>40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Superiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination</title>
        <description>Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 95% CI, directed against N. meningitidis serogroups A, C, W and Y, by hSBA at 1 month after one vaccination or two vaccinations of MenACWY-CRM. Seroresponse -postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer &lt;1:4 and for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.</description>
        <time_frame>One Month After Last Vaccination (day 86)</time_frame>
        <population>Analysis was done on the FAS dataset - All subjects in the exposed dataset who provided evaluable serum samples whose assay results were available for at least 1 serogroup on day 1 and 1 post baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Superiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination</title>
          <description>Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 95% CI, directed against N. meningitidis serogroups A, C, W and Y, by hSBA at 1 month after one vaccination or two vaccinations of MenACWY-CRM. Seroresponse -postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer &lt;1:4 and for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.</description>
          <population>Analysis was done on the FAS dataset - All subjects in the exposed dataset who provided evaluable serum samples whose assay results were available for at least 1 serogroup on day 1 and 1 post baseline visit.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA(N=158,163,171,163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O2" value="77" lower_limit="69" upper_limit="83"/>
                    <measurement group_id="O3" value="89" lower_limit="84" upper_limit="94"/>
                    <measurement group_id="O4" value="79" lower_limit="71" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC(N=154,157,167,162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="88" upper_limit="96"/>
                    <measurement group_id="O2" value="65" lower_limit="57" upper_limit="72"/>
                    <measurement group_id="O3" value="93" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O4" value="75" lower_limit="68" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW(N=150,154,167,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="O2" value="61" lower_limit="53" upper_limit="69"/>
                    <measurement group_id="O3" value="57" lower_limit="49" upper_limit="65"/>
                    <measurement group_id="O4" value="52" lower_limit="44" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY(N=150,153,167,163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="84" upper_limit="94"/>
                    <measurement group_id="O2" value="62" lower_limit="54" upper_limit="70"/>
                    <measurement group_id="O3" value="89" lower_limit="83" upper_limit="93"/>
                    <measurement group_id="O4" value="60" lower_limit="52" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (2 through 5 years of age) for MenA was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group Differences at Day 86</param_type>
            <param_value>18</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.1</ci_lower_limit>
            <ci_upper_limit>28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (2 through 5 years of age) for MenC was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group Differences at Day 86</param_type>
            <param_value>28</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_lower_limit>17.1</ci_lower_limit>
            <ci_upper_limit>38.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (2 through 5 years of age) for MenW was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenW</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group differences at Day 86</param_type>
            <param_value>14</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>27.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (2 through 5 years of age) for MenY was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenY</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine groups Differences at Day 86</param_type>
            <param_value>28</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.2</ci_lower_limit>
            <ci_upper_limit>39.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (6 through 10 years of age) for MenA was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenA</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine groups differences at Day 86</param_type>
            <param_value>11</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>21.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (6 through 10 years of age) for MenC was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group differences at Day 86</param_type>
            <param_value>18</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>27.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (6 through 10 years of age) for MenW was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenW</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Group Differences at Day 86</param_type>
            <param_value>5</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>18.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority for age cohort (6 through 10 years of age) for MenY was demonstrated if the lower limit of the 2-sided (1-2α) % CI for seroresponse increase between the 2-dose vaccination schedule and the 1-dose vaccination schedule was above 10% for MenY</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine group Differences at Day 86</param_type>
            <param_value>29</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17</ci_lower_limit>
            <ci_upper_limit>39.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM</title>
        <description>Immunogenicity was measured as the percentage of subjects who achieved hSBA titer ≥1:8 and associated 95% CI, at one month after one vaccination or two vaccinations of MenACWY-CRM.</description>
        <time_frame>One Month After Last Vaccination (day 86)</time_frame>
        <population>Analysis was done on the primary PP dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM</title>
          <description>Immunogenicity was measured as the percentage of subjects who achieved hSBA titer ≥1:8 and associated 95% CI, at one month after one vaccination or two vaccinations of MenACWY-CRM.</description>
          <population>Analysis was done on the primary PP dataset.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA(N=135,143,152,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O2" value="76" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="O3" value="91" lower_limit="85" upper_limit="95"/>
                    <measurement group_id="O4" value="80" lower_limit="73" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC(N=131,140,149,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="76" lower_limit="68" upper_limit="83"/>
                    <measurement group_id="O3" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O4" value="89" lower_limit="82" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW(N=128,135,148,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="92" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O4" value="96" lower_limit="91" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY(N=128,133,148,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91" upper_limit="99"/>
                    <measurement group_id="O2" value="69" lower_limit="61" upper_limit="77"/>
                    <measurement group_id="O3" value="96" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O4" value="73" lower_limit="64" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM</title>
        <description>Immunogenicity was measured as hSBA geometric mean titers (GMTs) and 95% CI against N. meningitidis serogroups A, C, W and Y, one month after one vaccination or two vaccinations of MenACWY-CRM.</description>
        <time_frame>One Month After Last Vaccination (day 86)</time_frame>
        <population>Analysis was done on the primary PP dataset</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM</title>
          <description>Immunogenicity was measured as hSBA geometric mean titers (GMTs) and 95% CI against N. meningitidis serogroups A, C, W and Y, one month after one vaccination or two vaccinations of MenACWY-CRM.</description>
          <population>Analysis was done on the primary PP dataset</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA(N=135,143,152,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="54" upper_limit="86"/>
                    <measurement group_id="O2" value="21" lower_limit="17" upper_limit="27"/>
                    <measurement group_id="O3" value="67" lower_limit="52" upper_limit="87"/>
                    <measurement group_id="O4" value="36" lower_limit="28" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC(N=131,140,149,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" lower_limit="115" upper_limit="186"/>
                    <measurement group_id="O2" value="22" lower_limit="18" upper_limit="28"/>
                    <measurement group_id="O3" value="165" lower_limit="126" upper_limit="217"/>
                    <measurement group_id="O4" value="67" lower_limit="51" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW(N=128,135,148,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191" lower_limit="150" upper_limit="243"/>
                    <measurement group_id="O2" value="104" lower_limit="83" upper_limit="132"/>
                    <measurement group_id="O3" value="169" lower_limit="138" upper_limit="206"/>
                    <measurement group_id="O4" value="95" lower_limit="78" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY(N=128,133,148,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="55" upper_limit="90"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="O3" value="76" lower_limit="58" upper_limit="99"/>
                    <measurement group_id="O4" value="26" lower_limit="20" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM</title>
        <description>Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI at one year after one vaccination or two vaccinations of MenACWY-CRM.</description>
        <time_frame>One year after one vaccination or two vaccinations (day 422).</time_frame>
        <population>Analysis was done on the persistence PP dataset</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM</title>
          <description>Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI at one year after one vaccination or two vaccinations of MenACWY-CRM.</description>
          <population>Analysis was done on the persistence PP dataset</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA(N=122,131,142,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="22" upper_limit="39"/>
                    <measurement group_id="O2" value="11" lower_limit="6" upper_limit="17"/>
                    <measurement group_id="O3" value="30" lower_limit="22" upper_limit="38"/>
                    <measurement group_id="O4" value="20" lower_limit="14" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC(N=123,128,141,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="52" upper_limit="70"/>
                    <measurement group_id="O2" value="41" lower_limit="32" upper_limit="50"/>
                    <measurement group_id="O3" value="81" lower_limit="73" upper_limit="87"/>
                    <measurement group_id="O4" value="55" lower_limit="46" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW(N=121,127,139,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="85" upper_limit="96"/>
                    <measurement group_id="O2" value="91" lower_limit="84" upper_limit="95"/>
                    <measurement group_id="O3" value="94" lower_limit="89" upper_limit="97"/>
                    <measurement group_id="O4" value="90" lower_limit="84" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY(N=121,122,140,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="58" upper_limit="75"/>
                    <measurement group_id="O2" value="57" lower_limit="48" upper_limit="66"/>
                    <measurement group_id="O3" value="75" lower_limit="67" upper_limit="82"/>
                    <measurement group_id="O4" value="65" lower_limit="57" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM</title>
        <description>Immunogenicity was measured as hSBA GMTs and 95% CI against N. meningitidis serogroups A, C, W and Y at one year after one vaccination or two vaccinations of MenACWY-CRM.</description>
        <time_frame>One year after one vaccination or two vaccinations (day 422).</time_frame>
        <population>Analysis was done on the persistence PP dataset</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM</title>
          <description>Immunogenicity was measured as hSBA GMTs and 95% CI against N. meningitidis serogroups A, C, W and Y at one year after one vaccination or two vaccinations of MenACWY-CRM.</description>
          <population>Analysis was done on the persistence PP dataset</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA(N=122,131,142,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" lower_limit="3.91" upper_limit="5.71"/>
                    <measurement group_id="O2" value="2.66" lower_limit="2.22" upper_limit="3.19"/>
                    <measurement group_id="O3" value="4.66" lower_limit="3.75" upper_limit="5.81"/>
                    <measurement group_id="O4" value="3.56" lower_limit="2.84" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC(N=123,128,141,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.34" upper_limit="13"/>
                    <measurement group_id="O2" value="7.03" lower_limit="5.63" upper_limit="8.76"/>
                    <measurement group_id="O3" value="24" lower_limit="18" upper_limit="31"/>
                    <measurement group_id="O4" value="15" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW(N=121,127,139,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="39" upper_limit="62"/>
                    <measurement group_id="O2" value="39" lower_limit="31" upper_limit="49"/>
                    <measurement group_id="O3" value="64" lower_limit="52" upper_limit="79"/>
                    <measurement group_id="O4" value="47" lower_limit="38" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY(N=121,122,140,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O2" value="9.88" lower_limit="7.8" upper_limit="13"/>
                    <measurement group_id="O3" value="20" lower_limit="15" upper_limit="25"/>
                    <measurement group_id="O4" value="13" lower_limit="9.96" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of 2 to 5 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</title>
        <description>Safety was assessed as the number of 2 to 5 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM</description>
        <time_frame>From Days 1-7 after each vaccination</time_frame>
        <population>Analysis was done on the safety dataset i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Number of 2 to 5 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</title>
          <description>Safety was assessed as the number of 2 to 5 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM</description>
          <population>Analysis was done on the safety dataset i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema(N=173,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration(N=173,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (N=174,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Eating Habits(N=173,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness(N=173,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability(N=173,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature &gt;=38.0(N=174,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced erythema in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>4.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced induration in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>6.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced tenderness in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced change in eating habits in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced sleepiness in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced irritability in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced fever (≥38 °C) in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of 6 to 10 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</title>
        <description>Safety was assessed as the number of 6 to 10 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM</description>
        <time_frame>From Days 1-7 after each vaccination</time_frame>
        <population>Analysis was done on the safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of 6 to 10 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</title>
          <description>Safety was assessed as the number of 6 to 10 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM</description>
          <population>Analysis was done on the safety dataset</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythema(N=178,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration(N=178,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain(N=178,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite(N=177,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea(N=177,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue(N=177,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia(N=177,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia(N=177,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache(N=177,165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature&gt;=38.0(N=178,166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced erythema in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced induration in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced pain in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced loss of appetite in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced nausea in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced fatigue in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced myalgia in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced arthralgia in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced headache in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The safety of two vaccine groups was compared by calculating risk ratio of the proportions of subjects who experienced fever (≥38 °C) in the two doses versus in the one dose of MenACWY-CRM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Selected AEs After Any Vaccination</title>
        <description>Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 86 after one or two vaccination(s) of MenACWY-CRM</description>
        <time_frame>Day 1 to Day 86</time_frame>
        <population>Analysis was done on Safety Set Unsolicited AEs</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Selected AEs After Any Vaccination</title>
          <description>Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 86 after one or two vaccination(s) of MenACWY-CRM</description>
          <population>Analysis was done on Safety Set Unsolicited AEs</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs resulting in premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Selected AEs After Any Vaccination</title>
        <description>Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 422 after one or two vaccination(s) of MenACWY-CRM</description>
        <time_frame>Day 1 to Day 422</time_frame>
        <population>Analysis was done on safety set</population>
        <group_list>
          <group group_id="O1">
            <title>2 Through 5 Years (2 Vac)</title>
            <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O2">
            <title>2 Through 5 Years (1 Vac)</title>
            <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
          </group>
          <group group_id="O3">
            <title>6 Through 10 Years (2 Vac)</title>
            <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
          </group>
          <group group_id="O4">
            <title>6 Through 10 Years (1 Vac)</title>
            <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Selected AEs After Any Vaccination</title>
          <description>Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 422 after one or two vaccination(s) of MenACWY-CRM</description>
          <population>Analysis was done on safety set</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related medically attended AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs resulting in premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout study period</time_frame>
      <desc>Serious adverse events (SAEs) were collected from day 1 to study termination/early termination.</desc>
      <group_list>
        <group group_id="E1">
          <title>2 Through 5 Years (2 Vac)</title>
          <description>Subjects 2-5 years of age received two MenACWY-CRM vaccinations</description>
        </group>
        <group group_id="E2">
          <title>2 Through 5 Years (1 Vac)</title>
          <description>Subjects 2-5 years of age received one MenACWY-CRM vaccination</description>
        </group>
        <group group_id="E3">
          <title>6 Through 10 Years (2 Vac)</title>
          <description>Subjects 6-10 years of age received two MenACWY-CRM vaccinations</description>
        </group>
        <group group_id="E4">
          <title>6 Through 10 Years (1 Vac)</title>
          <description>Subjects 6-10 years of age received one MenACWY-CRM vaccination</description>
        </group>
        <group group_id="E5">
          <title>Total</title>
          <description>Total Population</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0v</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IMMUNE THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PETIT MAL EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INTERMITTENT EXPLOSIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>OPPOSITIONAL DEFIANT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0v</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="133" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="576" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="232" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="193" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="120" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="392" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="115" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="114" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="114" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="103" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="108" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="179"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>registrycontactvaccinesus@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

